Stock Image

IMV Overview

IMV operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19.The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities.Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma).DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials.The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A.The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada. (From: StockAnalysis.com)


Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.